This page has only limited features, please log in for full access.

Unclaimed
Brian A. Vega
Department of Oral Biology, Rutgers School of Dental Medicine, Newark, NJ 07103, USA

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Review
Published: 26 August 2019 in Toxins
Reads 0
Downloads 0

Aggregatibacter actinomycetemcomitans is an oral pathogen that produces the RTX toxin, leukotoxin (LtxA; Leukothera®). A. actinomycetemcomitans is strongly associated with the development of localized aggressive periodontitis. LtxA acts as a virulence factor for A. actinomycetemcomitans to subvert the host immune response by binding to the β2 integrin lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18) on white blood cells (WBCs), causing cell death. In this paper, we reviewed the state of knowledge on LtxA interaction with WBCs and the subsequent mechanisms of induced cell death. Finally, we touched on the potential therapeutic applications of LtxA (trade name Leukothera®) toxin therapy for the treatment of hematological malignancies and immune-mediated diseases.

ACS Style

Brian A. Vega; Benjamin A. Belinka Jr.; Scott C. Kachlany. Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera®): Mechanisms of Action and Therapeutic Applications. Toxins 2019, 11, 489 .

AMA Style

Brian A. Vega, Benjamin A. Belinka Jr., Scott C. Kachlany. Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera®): Mechanisms of Action and Therapeutic Applications. Toxins. 2019; 11 (9):489.

Chicago/Turabian Style

Brian A. Vega; Benjamin A. Belinka Jr.; Scott C. Kachlany. 2019. "Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera®): Mechanisms of Action and Therapeutic Applications." Toxins 11, no. 9: 489.